Cannabinoid Encyclopedia

Focused research review

Does CBG help with inflammation?

CBG has anti-inflammatory signals in cells and animal models. These early findings do not establish that it treats inflammatory disease in people.

Updated July 2026 24 research sources Mostly early-stage research

The short answer

What is the bottom line?

CBG inflammation research is early and mostly non-human. 1 2 3

The approved source set includes experimental bowel, liver, and other inflammation models, along with mechanism-focused literature. These studies can test pathways and model outcomes, but they do not answer whether CBG changes an inflammatory condition in people. 1 2 3

What this means: A reduced inflammatory marker or improved animal model is not a treatment result for a person. Human population, disease, product, dose, route, and safety evidence are still needed for that question. 1 2 3

How to read this answer: A reduced inflammatory marker or improved animal model is not a treatment result for a person. Human population, disease, product, dose, route, and safety evidence are still needed for that question. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CBG and inflammation.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Most CBG inflammation sources are cellular, animal, or mechanism-focused rather than controlled human studies. 1

  2. 2

    Inflammatory bowel, liver, and other experimental models are not interchangeable with a human diagnosis. 2

  3. 3

    A pathway or marker change is not the same as evidence that CBG treats inflammatory disease. 3

Choose your question

What kind of inflammation question are you asking?

Inflammation research can describe a cell signal, an animal model, or a human outcome. Those are not interchangeable levels of evidence.

  1. 01Reader question

    What models were studied?

    See the bowel, liver, and other experimental contexts represented in the source set.

    Explore the evidence
  2. 02Reader question

    Does a marker change show a treatment effect?

    No. Read why biological changes and human outcomes need to stay separate.

    Explore the evidence
  3. 03Reader question

    What would stronger evidence look like?

    Human studies would need a clear condition, product, dose, comparator, outcome, and safety reporting.

    Explore the evidence

Research areas

What researchers studied about CBG and inflammation

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Mostly mechanism-focused

Inflammation-related outcomes

This part of the literature focuses on Inflammation-related outcomes. Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 1

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

5 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

6 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

13 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on CBG and inflammation is not one kind of study. This source set includes 16 animal studies, 4 narrative or expert reviews, 2 cell or laboratory studies, and 2 systematic reviews or meta-analyses. 3

The recorded populations or models include animal models (13 sources), people or patients (9 sources), and cells or tissue models (2 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is inflammation-related or immune outcomes (24 sources). Closely related outcome names can still describe different measurements. 5

The CBG and inflammation source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

animal study

Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease.

On this page, this source examines CBG and inflammation-related outcomes. 1

Study type
animal study
Population or model
people or patients
Outcome focus
inflammation-related or immune outcomes
Evidence stage
mechanism-focused research

animal study

Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor.

On this page, this source examines CBG and inflammation-related outcomes. 2

Study type
animal study
Population or model
animal models
Outcome focus
inflammation-related or immune outcomes
Evidence stage
mechanism-focused research

animal study

Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis.

On this page, this source examines CBG and inflammation-related outcomes. 3

Study type
animal study
Population or model
people or patients
Outcome focus
inflammation-related or immune outcomes
Evidence stage
preclinical research

narrative or expert review

Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.

On this page, this source examines CBG and inflammation-related outcomes. 4

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
inflammation-related or immune outcomes
Evidence stage
evidence still limited

animal study

Orally administered Cannabigerol (CBG) in rats: Cannabimimetic actions, anxiety-like behavior, and inflammation-induced pain.

On this page, this source examines CBG and inflammation-related outcomes. 5

Study type
animal study
Population or model
animal models
Outcome focus
inflammation-related or immune outcomes
Evidence stage
preclinical research

Safety and limits

What should readers keep in mind?

Research on CBG and inflammation should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

Does CBG reduce inflammation?

The current source set contains early anti-inflammatory signals in cells and animal models, not established human treatment evidence. 7

Does animal inflammatory bowel research show that CBG treats IBD?

No. Experimental bowel models can guide research, but they do not establish a treatment result for people with inflammatory bowel disease. 8

Why are inflammatory markers not enough?

Markers and pathways can change without showing that a human symptom, disease course, or safety outcome changes in a meaningful way. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. animal study; mechanism-focused research PubMed 23415610 DOI 10.1016/j.bcp.2013.01.017
  2. 2
    Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor. animal study; mechanism-focused research PubMed 36615835 DOI 10.3390/nu15010178
  3. 3
    Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis. animal study; preclinical research PubMed 39921943 DOI 10.1016/j.jpet.2025.103389
  4. 4
    Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. narrative or expert review; evidence still limited PubMed 39598860 DOI 10.3390/molecules29225471
  5. 5
    Orally administered Cannabigerol (CBG) in rats: Cannabimimetic actions, anxiety-like behavior, and inflammation-induced pain. animal study; preclinical research PubMed 39322049 DOI 10.1016/j.pbb.2024.173883
  6. 6
    The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. systematic review or meta-analysis; evidence still limited PubMed 33998900 DOI 10.1089/can.2020.0105
  7. 7
    The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis. systematic review or meta-analysis; evidence still limited PubMed 29562280 DOI 10.1093/ibd/izy014
  8. 8
    Cannabigerol and cannabichromene in Cannabis sativa L. narrative or expert review; evidence still limited PubMed 36654096 DOI 10.2478/acph-2021-0021
  9. 9
    Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action. narrative or expert review; evidence still limited PubMed 35614947 DOI 10.3389/fphar.2022.908198
  10. 10
    Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. narrative or expert review; evidence still limited PubMed 21749363 DOI 10.1111/j.1476-5381.2011.01238.x
  11. 11
    Cannabigerol Alleviates Liver Damage in Metabolic Dysfunction-Associated Steatohepatitis Female Mice via Inhibition of Transforming Growth Factor Beta 1. animal study; mechanism-focused research PubMed 40362835 DOI 10.3390/nu17091524
  12. 12
    Cannabigerol as an anti-inflammatory agent altering the level of arachidonic acid derivatives in the colon tissue of rats subjected to a high-fat high-sucrose diet. animal study; preclinical research PubMed 39128189 DOI 10.1016/j.biopha.2024.117286
See all 24 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. narrative or expert review; evidence still limited / 1 linked research note PubMed 39598860
  2. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. narrative or expert review; evidence still limited / 1 linked research note PubMed 21749363
  3. Orally administered Cannabigerol (CBG) in rats: Cannabimimetic actions, anxiety-like behavior, and inflammation-induced pain. animal study; preclinical research / 1 linked research note PubMed 39322049
  4. The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 33998900
  5. Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis. animal study; preclinical research / 1 linked research note PubMed 39921943
  6. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. animal study; mechanism-focused research / 1 linked research note PubMed 23415610
  7. Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice. animal study; preclinical research / 1 linked research note PubMed 39699828
  8. Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor. animal study; mechanism-focused research / 1 linked research note PubMed 36615835
  9. Cannabigerol attenuates liver fibrosis via AMPK activation: Regulation of lipid metabolism, inflammation, and hepatic stellate cell activation. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 40818359
  10. Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action. narrative or expert review; evidence still limited / 1 linked research note PubMed 35614947
  11. Targeting Vascular and Inflammatory Crosstalk: Cannabigerol as a Dual-Pathway Modulator in Rosacea. animal study; mechanism-focused research / 1 linked research note PubMed 40725084
  12. Cannabigerol Reduces Lipid Peroxidation Influencing Oxidative Stress and Inflammation Signaling Pathways in Melanocytes Exposed to UVA Radiation. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 41914282
  13. Cannabigerol Exerts In Vivo and In Vitro Anti-Inflammatory Effects via Inhibition of the MAPK and NF-κB Pathways. animal study; mechanism-focused research / 1 linked research note PubMed 41423277
  14. Cannabigerol Alleviates Liver Damage in Metabolic Dysfunction-Associated Steatohepatitis Female Mice via Inhibition of Transforming Growth Factor Beta 1. animal study; mechanism-focused research / 1 linked research note PubMed 40362835
  15. High Cannabigerol Hemp Extract Moderates Colitis and Modulates the Microbiome in an Inflammatory Bowel Disease Model. animal study; preclinical research / 1 linked research note PubMed 39009468
  16. Sphingolipid metabolism and insulin resistance - Does cannabigerol protect against experimental colitis induced by high-fat high-sucrose diet? animal study; mechanism-focused research / 1 linked research note PubMed 41056638
  17. Cannabigerol and cannabichromene in Cannabis sativa L. narrative or expert review; evidence still limited / 1 linked research note PubMed 36654096
  18. The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 29562280
  19. Orally Administered CBD/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model. animal study; preclinical research / 1 linked research note PubMed 40943856
  20. Cannabigerol as an anti-inflammatory agent altering the level of arachidonic acid derivatives in the colon tissue of rats subjected to a high-fat high-sucrose diet. animal study; preclinical research / 1 linked research note PubMed 39128189
  21. Development of a Rapid LC-MS/MS Method for the Quantification of Cannabidiol, Cannabidivarin, Δ9-Tetrahydrocannabivarin, and Cannabigerol in Mouse Peripheral Tissues. animal study; evidence still limited / 1 linked research note PubMed 28343385
  22. Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation. animal study; preclinical research / 1 linked research note PubMed 32996187
  23. Therapeutic Potential of Phytocannabinoid Cannabigerol for Multiple Sclerosis: Modulation of Microglial Activation In Vitro and In Vivo. animal study; mechanism-focused research / 1 linked research note PubMed 36830745
  24. Cannabigerol Attenuates Memory Impairments, Neurodegeneration, and Neuroinflammation Caused by Transient Global Cerebral Ischemia in Mice. animal study; preclinical research / 1 linked research note PubMed 40869376